-
1.发明授权公开(公告)号：US12233113B2
公开(公告)日：2025-02-25
申请号：US16077177
申请日：2017-02-16
Applicant: GENEXINE, INC. , HANDOK INC.
Inventor： Tae Kyung Kim , Young Joo Ahn , Jung Won Woo , Ji-Eun Cha , Joan Yoon Ji Lee , Woo Ick Jang
Abstract: Provided are a method for administering a recombinant human growth hormone GX-H9 for treating growth hormone deficiency and a pharmaceutical composition containing a recombinant human growth hormone GX-H9 and a pharmaceutically acceptable carrier. The method includes administering recombinant human growth hormone GX-H9 once a week with a dosage of 0.1 to 0.3 mg per weight kg of a patient or twice-monthly with a dosage of 0.1 to 0.4 mg per weight kg of the patient.
-
2.发明申请公开(公告)号：US20190224281A1
公开(公告)日：2019-07-25
申请号：US16329317
申请日：2017-08-30
Applicant: GENEXINE, INC. , HANDOK INC.
Inventor： Tae Kyung KIM , Jung Won WOO , Joan Yoon Ji LEE , Young-Joo AHN , Ji-Eun CHA , Hyou Young RHIM , Woo Ick JANG
Abstract: A method for treating growth hormone deficiency, including administering a human growth hormone fusion protein (GX-H9). A method includes administering a pharmaceutical composition containing an hGH fusion protein (GX-H9) and a pharmaceutically acceptable carrier, wherein the fusion protein (GX-H9) is administered once a week at a dose of 0.4 to 1.6 mg per body weight kg of a pediatric patient, or administered once every two weeks at a dose of 0.8 to 3.2 mg per body weight kg of a pediatric patient.
-
公开(公告)号：US20150351835A1
公开(公告)日：2015-12-10
申请号：US14763382
申请日：2014-02-05
Applicant: HANDOK INC.
Inventor： In-Je Hwang , Hae-Won Jang , Seung-Woo Song , Woo-Ick Jang
IPC: A61B18/14
CPC classification number: A61B18/1492 , A61B2018/00404 , A61B2018/00434 , A61B2018/00511 , A61B2018/00577 , A61B2018/1465 , A61B2018/1467
Abstract: A catheter for denervation includes a catheter body extending in one direction to have a proximal end and a distal end and having an inner space formed along the longitudinal direction thereof, a movable member provided at the distal end of the catheter body to be movable along the longitudinal direction of the catheter body, an operating member having a distal end connected to the movable member to move the movable member, a plurality of support members having one end connected to a terminal of the catheter body and the other end connected to the movable member, wherein when the movable member moves to decrease a distance between the terminal of the catheter body and the movable member, at least a partial portion of the plurality of support members is bent so that the bending portion moves away from the catheter body, a plurality of electrodes respectively provided at the bending portion of the plurality of support members to generate heat, and a lead wire respectively electrically connected to the plurality of electrodes to give a power supply path for the plurality of electrodes.
Abstract translation: 用于去神经支配的导管包括导管主体，所述导管主体在一个方向上延伸以具有近端和远端，并且具有沿着其纵向方向形成的内部空间;可移动构件，设置在导管主体的远端处， 导管主体的纵向方向;操作构件，其远端连接到可移动构件以移动可移动构件;多个支撑构件，其一端连接到导管主体的端子，另一端连接到可动构件 其特征在于，当所述可移动部件移动以减小所述导管主体的端子与所述可动部件之间的距离时，所述多个支撑部件的至少一部分被弯曲，使得所述弯曲部分远离所述导管主体移动， 分别设置在多个支撑构件的弯曲部分处以产生热量的电极，以及引线分别电连接 连接到多个电极以给出用于多个电极的电源路径。
-
4.发明申请公开(公告)号：US20210177945A1
公开(公告)日：2021-06-17
申请号：US16077177
申请日：2017-02-16
Applicant: GENEXINE, INC. , HANDOK INC.
Inventor： Tae Kyung Kim , Young_Joo Ahn , Jung Won Woo , Ji-Eun Cha , Joan Yoon Ji Lee , Woo Ick Jang
Abstract: Provided is a method for administering a recombinant human growth hormone GX-H9 for treating growth hormone deficiency. Particularly, the present disclosure relates to a pharmaceutical composition for treating growth hormone deficiency, containing a recombinant hGH GX-H9 and a pharmaceutically acceptable carrier, in which the recombinant GX-H9 is administered once a week with a dosage of 0.1 to 0.3 mg per weight kg of a patient or twice-monthly with a dosage of 0.1 to 0.4 mg per weight kg of the patient. Further, the present disclosure relates to a method for treating growth hormone deficiency including administering an recombinant hGH GX-H9 to a patient with growth hormone deficiency once a week with a dosage of 0.1 to 0.3 mg per weight kg of the patient or twice-monthly with a dosage of 0.1 to 0.4 mg per weight kg of the patient.
-
公开(公告)号：US20150259350A1
公开(公告)日：2015-09-17
申请号：US14435974
申请日：2013-09-30
Inventor： Hee Jung Jung , Jae Du Ha , Sung Yun Cho , Hyoung Rae Kim , Kwang Ho Lee , Chong Ock Lee , Sang Un Choi , Chi Hoon Park
IPC: C07D487/04
CPC classification number: C07D487/04 , A61K31/4985
Abstract: The present invention relates to a novel triazolopyrazine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating hyper proliferative disorder. The present invention can be useful as a therapeutic agent for various hyper proliferative disorders associated with excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy, by efficiently inhibiting c-Met tyrosine kinase activity.
Abstract translation: 本发明涉及一种新型的三唑并吡嗪衍生物或其药学上可接受的盐，以及含有其作为预防或治疗高增殖性病症的活性成分的药物组合物。 通过有效抑制c-Met酪氨酸激酶活性，本发明可用作与由异常激酶活性如癌症，银屑病，类风湿性关节炎和糖尿病性视网膜病引起的过度细胞增殖和生长相关的各种高增殖性疾病的治疗剂 。
-
Patent Agency Ranking
公开(公告)号：US09701681B2
公开(公告)日：2017-07-11
申请号：US14968208
申请日：2015-12-14
Applicant: CMG Pharmaceutical Co., Ltd. , HANDOK INC.
Inventor： Moonsoo Kim , Chaewoon Lee , Gilnam Lee , Cheol Hwan Yoon , Jeongbeob Seo , Je Hak Kim , MinWoo Lee , Hankyul Jeong , Hyang Choi , Myung Eun Jung , Kinam Lee , Hyun Jung Kim , Hye Kyoung Kim , Jae Il Lee , Misoon Kim , Soongyu Choi
IPC: C07D487/04
CPC classification number: C07D487/04 , A61P29/00 , A61P35/00 , A61P37/00
Abstract: The disclosure provides novel chemical compounds represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. The compounds can be used as an inhibitor of Trk and are useful in the treatment of pain, cancer, inflammation, neurodegenerative disease and certain infectious diseases. In some compounds of Formula I, Q is —CH═CR3C(O)NR4R5, —C≡CC(O)NR4R5, or
-
公开(公告)号：US20250026804A1
公开(公告)日：2025-01-23
申请号：US18713500
申请日：2022-10-19
Applicant: Genexine, Inc. , HANDOK INC.
Inventor： Chanwoong PARK , Ki-Yong KIM
Abstract: A high-concentration formulation of hGH fusion protein containing poloxamer 188 and polysorbate 80 and uses thereof are disclosed. The formulation containing poloxamer 188 and polysorbate 80 contains a high-concentration of hGH fusion protein has significantly reduced aggregation reactions and improved storage stability. The formulation can be a liquid formulation. The hGH fusion protein includes hGH and an immunoglobulin Fc polypeptide.
-
8.发明授权公开(公告)号：US10196396B2
公开(公告)日：2019-02-05
申请号：US15406556
申请日：2017-01-13
Applicant: HANDOK INC.
Inventor： Jin-Hwa Lee , Seung-Yong Kim , Do-Ran Kim , Koo-Hyeon Ahn , Gwi-Bin Lee , Doo-Seop Kim , Hyun-Sook Hwang
IPC: A01N43/04 , A61K31/70 , C07D487/04 , C07D519/00 , A61K31/7068 , A61K31/7064 , A61K31/706
Abstract: The present disclosure provides compounds useful in the amelioration, prevention or treatment of A3 adenosine receptor mediated diseases, such as glaucoma and glaucoma-related ocular disorders, having the structure of Formula I as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for ameliorating, preventing or treating A3 adenosine receptor mediated diseases using the compound.
-
9.发明申请公开(公告)号：US20170204101A1
公开(公告)日：2017-07-20
申请号：US15406556
申请日：2017-01-13
Applicant: HANDOK INC.
Inventor： Jin-Hwa Lee , Seung-Yong Kim , Do-Ran Kim , Koo-Hyeon Ahn , Gwi-Bin Lee , Doo-Seop Kim , Hyun-Sook Hwang
IPC: C07D487/04 , C07D519/00
CPC classification number: C07D487/04 , A61K31/706 , A61K31/7064 , A61K31/7068 , C07D519/00
Abstract: The present disclosure provides compounds useful in the amelioration, prevention or treatment of A3 adenosine receptor mediated diseases, such as glaucoma and glaucoma-related ocular disorders, having the structure of Formula I as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for ameliorating, preventing or treating A3 adenosine receptor mediated diseases using the compound.
-
公开(公告)号：US09403831B2
公开(公告)日：2016-08-02
申请号：US14435974
申请日：2013-09-30
Inventor： Hee Jung Jung , Jae Du Ha , Sung Yun Cho , Hyoung Rae Kim , Kwang Ho Lee , Chong Ock Lee , Sang Un Choi , Chi Hoon Park
IPC: C07D487/04 , A61K31/4985
CPC classification number: C07D487/04 , A61K31/4985
Abstract: The present invention relates to a novel triazolopyrazine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating hyper proliferative disorder. The present invention can be useful as a therapeutic agent for various hyper proliferative disorders associated with excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy, by efficiently inhibiting c-Met tyrosine kinase activity.
Abstract translation: 本发明涉及一种新型的三唑并吡嗪衍生物或其药学上可接受的盐，以及含有其作为预防或治疗高增殖性病症的活性成分的药物组合物。 通过有效抑制c-Met酪氨酸激酶活性，本发明可用作与由异常激酶活性如癌症，银屑病，类风湿性关节炎和糖尿病性视网膜病引起的过度细胞增殖和生长相关的各种高增殖性疾病的治疗剂 。
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.02 seconds)
